Phase 3 data presented at ASCO 2026 suggest a PSMA-targeted [...]
Kairos Pharma, Ltd. will present positive safety and early efficacy [...]
Kairos Pharma has announced encouraging interim efficacy results from its [...]
Phase 3 data presented at ASCO 2026 suggest a PSMA-targeted [...]
Kairos Pharma, Ltd. will present positive safety and early efficacy [...]
Kairos Pharma has announced encouraging interim efficacy results from its [...]